OTLK · Outlook Therapeutics, Inc.
$0.98
-0.05 (-5.02%)
At close · Aug 6
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$124.49M
Shares
120.86M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.03
Open$0.95
Day$0.94–1.04
52W$0.16–3.39
Avg vol 30d12.7M
Short int11.2M · 9.3% float · 1.2d
Short vol54%
Last earningsAug 14, 2024
DataJan 2020–Aug 2026
Filing10-Q · May 15
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
−17%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
27%
mid-range
Momentum
relative strength
1-month return
−39%
trailing
6-month return
+120%
trailing
YTD return
−35%
this year
Relative strength
+108%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
19 of 56 funds reported for Jun 30 · net -280.5K sh shares · +8 new
Insider flow
Accumulating
Net +$5.4M over 90 days · 0% sells
Short interest
Falling
9.30% of float · ▼ -19.8% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
56 holders — near 3-yr low, contrarian setup
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+164%
Y/Y
Gross margin
1%
EPS growth
+56%
Y/Y
Free cash flow
$-52.3M
Balance sheet
$42.8M
net debt
Quant / Vol
risk profile
Volatility
164%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
17.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
−17%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
19 of 56 funds reported for Jun 30 · net -280.5K sh shares · +8 new
Insider flow
Accumulating
Net +$5.4M over 90 days · 0% sells
Short interest
Falling
9.30% of float · ▼ -19.8% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
56 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $0
Now $1 · 27%
52-wk high $3
vs 200-day avg +11%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OTLK
this stock
Outlook Therapeutics, Inc.
|
$124.49M | -34.8% | +163.8% | — | 9.3% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OTLK | +3.0% | -39.1% | +119.6% | +5.4% | -34.8% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -2.5% | -42.3% | +108.4% | +2.4% | -47.7% |
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
16 filings
16 filers
Visit website
Investor relations